Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
88M
-
Shares change
-
+262K
-
Total reported value, excl. options
-
$723M
-
Value change
-
+$2.54M
-
Put/Call ratio
-
1.32
-
Number of buys
-
97
-
Number of sells
-
-77
-
Price
-
$8.22
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q2 2024
206 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 88M shares
of 89.4M outstanding shares and own 98.37% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.64M shares), ARMISTICE CAPITAL, LLC (7.5M shares), Deep Track Capital, LP (7.37M shares), VANGUARD GROUP INC (6.62M shares), Rock Springs Capital Management LP (4.48M shares), MACQUARIE GROUP LTD (4.37M shares), STATE STREET CORP (3.51M shares), MORGAN STANLEY (3.49M shares), MILLENNIUM MANAGEMENT LLC (2.95M shares), and Assenagon Asset Management S.A. (2.21M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.